As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
|Articles|November 18, 2021
Pharmacy Clinical Pearl of the Day: Endometrial Cancer
Author(s)Saro Arakelians, PharmD
Treatment for endometrial cancer includes surgery, radiation therapy, chemotherapy, immunotherapy, and supportive care.
Advertisement
Clinical Pearl of the Day: Endometrial Cancer
Endometrial cancer is a type of the disease that begins in the uterus.
Insight:
- The uterus is the hollow, pear-shaped pelvic organ where fetal development occurs.
- Symptoms include vaginal bleeding after menopause, bleeding between periods, and pelvic pain.
- Risk factors include changes in the hormone balances, menstruation starting before 12 years of age, never being pregnant, older age, obesity, hormone therapy for breast cancer, and history of colon cancer.
- Diagnosis includes examining the pelvis, using sound waves to create a picture of the uterus, scoping the endometrium, sample biopsy, and performing surgery
- Treatment for endometrial cancer includes surgery, radiation therapy, chemotherapy, hormone therapy, targeted drug therapy, immunotherapy, and supportive care.
- Some of the chemotherapy medications for endometrial cancer paclitaxel (Taxol), carboplatin, doxorubicin (Adriamycin), cisplatin and docetaxel (Taxotere).
Sources:
Advertisement
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5